Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02400385
Title A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors California Pacific Medical Center Research Institute
Indications

melanoma

Therapies

Nivolumab + Sunitinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST